Patents Examined by Wu-Cheng Winston Shen
  • Patent number: 9249101
    Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: February 2, 2016
    Assignee: CLINO LTD.
    Inventors: Yukitsuka Kudo, Shozo Furumoto, Nobuyuki Okamura
  • Patent number: 9241927
    Abstract: The present invention relates to a pharmaceutical composition that comprises a compound of formula (I) as active pharmaceutical ingredient: or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof; and at least a pharmaceutically acceptable excipient, wherein the active pharmaceutical ingredient is present in an amount of at least 80% of the total dry weight of the composition.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: January 26, 2016
    Assignee: Laboratories Del Dr, Esteve, S.A.
    Inventors: Luis Soler Ranzani, Pierandrea Esposito, Gemma Casadevall Pujals, Nuria Cubel Suñé
  • Patent number: 9238016
    Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 19, 2016
    Inventors: Kyeong Kyu Kim, Sung Wook Kang
  • Patent number: 9238659
    Abstract: Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 19, 2016
    Inventors: Chi Ming Che, Taotao Zou
  • Patent number: 9233952
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: January 12, 2016
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • Patent number: 9226924
    Abstract: A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel ?2? ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent used in the method includes as effective ingredients a cyclohexane derivative or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel ?2? ligand.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 5, 2016
    Assignee: Toray Industries, Inc.
    Inventors: Naoki Izumimoto, Hidenori Mochizuki
  • Patent number: 9227979
    Abstract: Disclosed are compounds of the formula (I) which are fluorescently labeled antagonists of the A3 adenosine receptor: wherein A, R1, R2, and Y are as described herein. Also disclosed are diagnostic compositions and a method of diagnosis of a patient for a possible treatment by an antagonist of the A3 adenosine receptor, involving the use of one or more of these compounds as diagnostic agents.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: January 5, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, Universita Degli Studi Di Trieste, Universita Degli Studi Di Padova
    Inventors: Kenneth A. Jacobson, Santhosh Kumar Thatikonda, Eszter Erika Kozma, Giampiero Spalluto, Stefano Moro, Stephanie Federico
  • Patent number: 9226919
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: January 5, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Samit Hirawat, Langdon Miller
  • Patent number: 9220714
    Abstract: The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 29, 2015
    Assignees: Brown University, Women and Infants' Hospital Rhode Island
    Inventors: Giselle L. Saulnier Sholler, Narasimha Swamy, Stayan Kalkunte, Rakesh K. Singh, Laurent Brard, Kyu Kwang Kim
  • Patent number: 9216222
    Abstract: The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, H2S poisoning as well as treatment for elevated blood pressure.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: December 22, 2015
    Inventors: Albert M. Zwiener, Kenneth H. Carson, Joseph A. McDonough, Larry A. Cabell, Norma L. Cantu, Sandra J. Drabik, Andrew P-Z. Clark, Paul M. Thompson, Richard Michael Corbett
  • Patent number: 9211262
    Abstract: Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilized powder with a carrier selected from lactose and dextran, mixed with sodium chloride.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: December 15, 2015
    Assignee: CTI BioPharma Corp.
    Inventors: Alberto Bernareggi, Valeria Livi
  • Patent number: 9211279
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: December 15, 2015
    Inventors: Christoph Boss, Christine Brotschi, John Gatfield, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Patent number: 9206124
    Abstract: A pharmaceutical composition, a method of producing same, and a method of providing cancer therapy therein comprising a pharmaceutically acceptable excipient or carrier and a compound Formula 3 as follows: or a pharmaceutically acceptable salt or prodrug thereof, wherein: R1, R2, R3 and R4 are optionally substituted and are hydrogen, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, acyloxyalkyl, hydroxyl, alkoxy, acetoxy, amino, alkylamino, acetamido.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: December 8, 2015
    Assignee: New Mexico Technical Research Foundation
    Inventors: Alexander V. Akensov, Snezna Rogelj, Liliya Frolova, Alexander Kornienko, Gabriel Avilucea
  • Patent number: 9206173
    Abstract: The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: December 8, 2015
    Inventors: Akira Takahashi, Masaki Suzuki, Yuichi Nakamura, Yohji Sakurai
  • Patent number: 9198922
    Abstract: Disclosed herein is a composition that includes a novel combination of triterpenoids for the treatment or prophylaxis of a cancer. The triterpenoids includes at least ganoderic acid S (GAS), ganoderic acid T (GAT), ganoderic acid Me (GAMe), ganoderic acid R (GAR), and ganodermic acid S (GMAS). The composition is suitable for the treatment or prophylaxis of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: December 1, 2015
    Assignee: Double Crane Biotechnology Co., Ltd.
    Inventors: Shwu-Bin Lin, Cheng-Po Huang, Teng-Hai Chen, Kuang-Dee Chen
  • Patent number: 9199937
    Abstract: Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: December 1, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Daniel Bischoff, Georg Dahmann, Jasna Klicic, Gerhard Schaenzle, Stefan Ludwig Michael Wollin, Serge Gaston Convers-Reignier, Stephen Peter East, Frederic Jacques Marlin, Clive McCarthy, John Scott
  • Patent number: 9187450
    Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: November 17, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Nakamura, Hidenori Namiki, Naoki Terasaka, Akiko Shima, Masahiko Hagihara, Noriaki Iwase, Katsunori Takata, Osamu Kikuchi, Kazunari Tsuboike, Hiroyuki Setoguchi, Kenji Yoneda, Hidetoshi Sunamoto, Koji Ito
  • Patent number: 9181184
    Abstract: The present invention provides a method for increasing the activity of a mutant or wild-type ?-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1-deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The 1-deoxynojirimycin derivative is substituted at the N or C1 position. Combination therapy with replacement ?-glucosidase gene or enzyme is also provided.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: November 10, 2015
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Benjamin Mugrage, Gary Lee, Xiaoxiang Zhu, Robert Boyd, Kamlesh Sheth
  • Patent number: 9174996
    Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: November 3, 2015
    Assignee: Astar Biotech LLC
    Inventors: Chunrong Yu, Haihong Huang, Dongfeng Zhang, Peng Li
  • Patent number: 9168306
    Abstract: This disclosure relates to cyclodextrin-based drug delivery agents that comprise a cyclodextrin moiety covalently linked to a moiety of a gemini surfactant. Pharmaceutical compositions comprising the drug delivery agent and a therapeutic agent are also disclosed.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: October 27, 2015
    Assignee: University of Saskatchewan
    Inventors: Ildiko Badea, Ronald Verrall, Peng Yang, Marianna Foldvari, Jackson Chitanda, Deborah Michel